Tarsus Posts Adjusted Loss of $0.78 per Share as Third-Quarter Revenue Tops Estimates
Key Facts
Tarsus Pharmaceuticals reported on November 3 results for the third quarter ended September 30, 2026, posting an adjusted loss of $0.78 per share. The loss was narrower than the Zacks consensus estimate of $1.43 per share, according to Zacks data. That represented a positive earnings surprise of 45.46% under the measure used by the platform. But the adjusted per-share loss remained larger than the $0.30 loss reported a year earlier. The improvement against expectations coincided with revenue growth, while the company remained loss-making on a per-share basis.
Quarterly revenue was $194.57 million, exceeding the Zacks consensus estimate by 3.06%. Revenue was $118.7 million in the third quarter of the prior year, according to Zacks. The comparison reflects higher sales between the periods, as well as a beat against analysts’ estimate for the current quarter. Revenue offers a different read from the per-share loss: sales came in above estimates, and the adjusted loss was narrower than expected. By contrast, an adjusted earnings surprise does not mean accounting net income exceeded analysts’ expectations.
Tarsus shares, which trade under the ticker TARS, closed at $72.64 on November 3, according to EL7 data. The close came on the day the company announced its third-quarter results. The price places the stock’s movement in the context of the results day, but on its own does not establish investors’ response to the reported figures. The results combined a revenue beat with an adjusted loss narrower than Zacks’ estimate. The year-over-year comparison also showed the adjusted per-share loss widening from $0.30 to $0.78.
Chief Executive Bobby Azamian said the company had dispensed more than one million bottles of Xdemvy and that cumulative net sales since its launch had topped $1 billion. He added that the company sees the potential to bring five medicines to patients over the next five years. On usage, Tarsus said the average number of eye-care professionals prescribing Xdemvy at least once a day rose by about 20% from the start to the end of the third quarter. Refills accounted for about 20% of the drug’s prescriptions during the quarter, the company said. Azamian said the company had “dispensed more than one million bottles and generated $1 billion in cumulative net product sales,” pointing to the potential to bring five medicines to patients over the next five years.
The company’s announced upcoming milestones include key data expected from the Phase 2 TP-04 and TP-05 trials in the first half of 2027. Tarsus also plans to begin the Phase 3 IRX-101 study in the first half of 2027, with topline results expected in 2028. The company is targeting 2029 for topline results from the Phase 3 study of gildeuretinol. These timelines place the trial program within the period in which the company said it aims to bring five medicines to patients. The upcoming trial data will mark announced milestones in its product development schedule.